Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has a beta value of 2.85 and has seen 0.47 million shares traded in the last trading session. The company, currently valued at $1.51B, closed the last trade at $54.28 per share which meant it lost -$2.94 on the day or -5.14% during that session. The ARCT stock price is -138.96% off its 52-week high price of $129.71 and 54.18% above the 52-week low of $24.87. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.55 million shares traded. The 3-month trading volume is 888.56K shares.
The consensus among analysts is that Arcturus Therapeutics Holdings Inc. (ARCT) is a Hold stock at the moment, with a recommendation rating of 2.70. 4 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 13 have rated it as a Hold, with 7 advising it as a Buy. 1 have rated the stock as Underweight. The expected earnings per share for the stock is -$2.15.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) trade information
Sporting -5.14% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the ARCT stock price touched $54.28 or saw a rise of 7.13%. Year-to-date, Arcturus Therapeutics Holdings Inc. shares have moved 25.13%, while the 5-day performance has seen it change -4.25%. Over the past 30 days, the shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have changed 0.65%. Short interest in the company has seen 4.06 million shares shorted with days to cover at 6.69.
Wall Street analysts have a consensus price target for the stock at $81.25, which means that the shares’ value could jump 33.19% from current levels. The projected low price target is $27.00 while the price target rests at a high of $152.00. In that case, then, we find that the current price level is -180.03% off the targeted high while a plunge would see the stock lose 50.26% from current levels.
Arcturus Therapeutics Holdings Inc. (ARCT) estimates and forecasts
Figures show that Arcturus Therapeutics Holdings Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 26.35% over the past 6 months, with this year growth rate of -70.70%, compared to 7.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -290.90% and -80.40% for the next quarter. Revenue growth from the last financial year stood is estimated to be 525.00%.
13 analysts offering their estimates for the company have set an average revenue estimate of $2 million for the current quarter. 12 have an estimated revenue figure of $20.12 million for the next quarter concluding in Sep 2021. Year-ago sales stood $3.54 million and $3 million respectively for this quarter and the next, and analysts expect sales will shrink by -43.50% for the current quarter and 570.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.80% over the past 5 years.
Arcturus Therapeutics Holdings Inc. is expected to release its next earnings report on May 10 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s Major holders
Insiders own 17.99% of the company shares, while shares held by institutions stand at 75.57% with a share float percentage of 92.15%. Investors are also buoyed by the number of investors in a company, with Arcturus Therapeutics Holdings Inc. having a total of 205 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 3.96 million shares worth more than $171.74 million. As of Dec 30, 2020, ARK Investment Management, LLC held 15.06% of shares outstanding.
The other major institutional holder is Federated Hermes, Inc., with the holding of over 3.45 million shares as of Dec 30, 2020. The firm’s total holdings are worth over $149.78 million and represent 13.14% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and Federated Hermes Kaufmann Fund. As of Mar 30, 2021, the former fund manager holds about 12.59% shares in the company for having 3.31 million shares of worth $136.66 million while later fund manager owns 1.9 million shares of worth $137.67 million as of Jan 30, 2021, which makes it owner of about 7.23% of company’s outstanding stock.